CoChat

Targeting adhesion signaling in KRAS, LKB1 mutant lung adenocarcinoma

Open access
Gilbert-Ross, Melissa, Konen, Jessica, Koo, Junghui, Shupe, John, Robinson, Brian S., Wiles, Walter Guy, Huang, Chunzi, Martin, W. David, Behera, Madhusmita, Smith, Geoffrey H., Hill, Charles E., Rossi, Michael R., Sica, Gabriel L., Rupji, Manali, Chen, Zhengjia, Kowalski, Jeanne, Kasinski, Andrea L., Ramalingam, Suresh S., Fu, Haian, Khuri, Fadlo R., Zhou, Wei, Marcus, Adam I. · 2017 · JCI Insight
Cited by 57

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Loss of LKB1 activity is prevalent in KRAS mutant lung adenocarcinoma and promotes aggressive and treatment-resistant tumors. Previous studies have shown that LKB1 is a negative regulator of the focal adhesion kinase (FAK), but in vivo studies testing the efficacy of FAK inhibition in LKB1 mutant cancers are lacking. Here, we took a pharmacologic approach to show that FAK inhibition is an effective early-treatment strategy for this high-risk molecular subtype. We established a lenti-Cre–induced Kras and Lkb1 mutant genetically engineered mouse model ( KL Lenti ) that develops 100% lung adenocarcinoma and showed that high spatiotemporal FAK activation occurs in collective invasive cells that are surrounded by high levels of collagen. Modeling invasion in 3D, loss of Lkb1 , but not p53 , was sufficient to drive collective invasion and collagen alignment that was highly sensitive to FAK inhibition. Treatment of early, stage-matched KL Lenti tumors with FAK inhibitor monotherapy resulted in a striking effect on tumor progression, invasion, and tumor-associated collagen. Chronic treatment extended survival and impeded local lymph node spread. Lastly, we identified focally upregulated FAK and collagen-associated collective invasion in KRAS and LKB1 comutated human lung adenocarcinoma patients. Our results suggest that patients with LKB1 mutant tumors should be stratified for early treatment with FAK inhibitors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci.insight.90487

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 57

Metadata

Authors
Gilbert-Ross, M., Konen, J., Koo, J., Shupe, J., Robinson, B. S., Wiles, W. G., Huang, C., Martin, W. D., Behera, M., Smith, G. H., Hill, C. E., Rossi, M. R., Sica, G. L., Rupji, M., Chen, Z., Kowalski, J., Kasinski, A. L., Ramalingam, S. S., Fu, H., Khuri, F. R., Zhou, W., & Marcus, A. I.
Venue
JCI Insight
Published
2017-03-09
Volume
2
Issue
5
Pages
e90487-e90487
ISSN
2379-3708 (ISSN-L)
OpenAlex
W2594591478
Cited by
57
References
12
FWCI
3.44
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting adhesion signaling in KRAS, LKB1 mutant lung adenocarcinoma. https://app.cochat.ai/papers/10.1172/jci.insight.90487
The paper
Gilbert-Ross, M., Konen, J., Koo, J., Shupe, J., Robinson, B. S., Wiles, W. G., Huang, C., Martin, W. D., Behera, M., Smith, G. H., Hill, C. E., Rossi, M. R., Sica, G. L., Rupji, M., Chen, Z., Kowalski, J., Kasinski, A. L., Ramalingam, S. S., Fu, H., . . . Marcus, A. I. (2017). Targeting adhesion signaling in KRAS, LKB1 mutant lung adenocarcinoma. JCI Insight. https://doi.org/10.1172/jci.insight.90487

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.